<?xml version="1.0" encoding="UTF-8"?>
<p id="p0050">On May 15, 2020, President Trump announced a U.S. public-private partnership, the OWSVI (Operation Warp Speed Vaccine Initiative), to accelerate the development, manufacture, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. An explicit goal for the OWSVI is to make available hundreds of millions of doses of an effective vaccine—essentially enough to vaccinate the entire population of the United States—by January 2021 (
 <xref rid="bib9" ref-type="bibr">9</xref>). Given that only 15 vaccines were approved in the Unites States between 1995 and 2014, only 1 in 15 vaccines that enter phase II trials is ever licensed, and the average development time for vaccines is usually measured in decades (
 <xref rid="tbl1" ref-type="table">Table 1</xref>) (
 <xref rid="bib10" ref-type="bibr">10</xref>), this would indeed be a remarkable achievement.
</p>
